Is the price fair?
What AHCO's price assumes
Today's price asks for −8.9% free cash flow growth a year; over the last three years AdaptHealth Corp. delivered 63%, less than the record.
0.49
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 15%
Free cash flow yield · Medical Devices median 4.0%
- Growth the price implies
- −8.9%
Growth the price implies · The price pays for −8.9% free cash flow growth a year for a decade; the business has delivered +63% a year over the last three.
- Price / book
- 1.07
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 1.07
- EV / EBIToperating margin 2.2%: the multiple describes the denominator
- not meaningful
- EV / sales2026-Q1
- 1.03
- Free cash flow, trailing twelve months
- $192M
- Market capitalisation
- $1.31B
- 3-year revenue growth
- +3.0%
- 3-year free cash flow growth
- +63%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.